Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Werewolf Therapeutics, Inc. (Nasdaq: HOWL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company developing conditionally activated immune therapies, Werewolf uses its filings to report on financial condition, clinical progress, governance matters, and material corporate events.
Investors reviewing HOWL filings will find Form 8‑K current reports describing key developments such as pipeline and business updates, clinical data summaries for WTX-124 and WTX-330, strategic partnering objectives, and notices related to Nasdaq listing requirements. Results of operations and financial condition for specific quarters are furnished through 8‑K items that reference accompanying earnings press releases and corporate presentations.
Through its periodic reports and exhibits, Werewolf outlines the status of its PREDATOR platform, INDUKINE cytokine prodrugs, and INDUCER T cell engager programs, along with forward-looking statements that detail development timelines, regulatory engagement plans, and cash runway expectations. Governance-related disclosures, including board composition and audit committee matters, also appear in the company’s 8‑K filings.
On Stock Titan, HOWL filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the main points of lengthy filings, identify references to clinical trial updates, partnering strategies, or listing compliance, and navigate to specific sections of interest. Real-time updates from EDGAR help ensure that new filings are surfaced promptly, while access to historical documents allows for analysis of how Werewolf’s clinical pipeline, risk disclosures, and corporate priorities have evolved over time.
Werewolf Therapeutics, Inc. is a clinical-stage biotech developing conditionally activated cytokine therapies and T‑cell engagers for cancer and immune diseases using its PREDATOR platform. The company discloses substantial doubt about its ability to continue as a going concern and is exploring strategic alternatives, including a possible sale or merger.
In February 2026 it adopted a restructuring plan, reducing its workforce by 64% and expecting about $4.1 million of severance and related charges in the first quarter of 2026. Lead IL‑2 INDUKINE candidate WTX‑124 showed a 21% objective response rate as monotherapy in heavily pretreated metastatic melanoma and 30% in patients who were not primary resistant to immunotherapy, with an FDA‑accepted 18 mg recommended dose and initial monotherapy registration guidance in post‑ICI melanoma. IL‑12 INDUKINE WTX‑330 produced a confirmed partial response in metastatic gall bladder cancer with a 45% tumor reduction and favorable pharmacokinetics. Further advancement of all programs depends on additional funding and outcomes of the strategic review.
Werewolf Therapeutics reported fourth quarter and full-year 2025 results and launched a formal review of strategic alternatives that could include a sale, merger, asset sale, licensing deals or other transactions. The company hired Piper Sandler as exclusive financial advisor and emphasized there is no set timeline or assurance any deal will occur.
For the quarter ended December 31, 2025, net loss narrowed to $8.4M from $20.4M a year earlier, driven by lower research and development expenses of $6.9M versus $15.7M, and general and administrative expenses of $2.5M versus $4.6M. Full-year 2025 net loss improved to $60.8M from $70.5M, with R&D at $44.8M and G&A at $15.8M.
As of December 31, 2025, cash and cash equivalents were $57.1M, down from $111.0M a year earlier. The company expects this cash to fund operations into the fourth quarter of 2026, while it continues advancing its INDUKINE and INDUCER immune-oncology platforms and clinical candidates WTX-124 and WTX-330.
Werewolf Therapeutics, Inc. VP of Finance & Corporate Controller Michael J. Urban filed an initial Form 3 showing his equity holdings. He directly holds stock options covering 52,500 shares at an exercise price of $3.6500, 29,365 shares at $4.6400, 10,000 shares at $1.5700, and 54,800 shares at $1.5600, with expiration dates ranging from 2033 to 2035. He also directly owns 5,284 shares of Werewolf Therapeutics common stock.
Werewolf Therapeutics, Inc. announced that its board has initiated a process to explore a full range of strategic alternatives to advance its drug development platform and pipeline and to maximize stockholder value. The company has engaged Piper Sandler & Co. as its exclusive financial advisor for this evaluation.
Potential options under consideration include a sale of the company, a business combination or merger, a sale of assets, licensing or collaboration arrangements, or other strategic transactions. Werewolf stated it has no defined timeline for this review and there is no assurance that the process will result in any transaction or agreement, and it does not intend to provide further updates unless a specific action is approved or additional disclosure is deemed appropriate.
Werewolf Therapeutics, Inc. approved a major restructuring that will cut 64% of its workforce, with the reduction expected to be largely complete by February 13, 2026. The company plans to record an estimated $4.1 million one-time charge in the first quarter of 2026 for severance and related cash benefits.
As part of this action, Chief Financial Officer Timothy W. Trost and Chief Medical Officer Dr. Randi Isaacs will resign their roles effective February 13, 2026, each receiving severance equal to nine months of base salary plus nine months of company-paid COBRA contributions and extended stock option exercise periods. Both will continue under consulting agreements at $250 per hour for up to six months. The company appointed Michael Urban, previously Vice President of Finance and Corporate Controller, as principal financial and accounting officer effective February 13, 2026.
The company also disclosed that in late 2025 and early 2026 it sought to raise capital and is now evaluating alternatives to maximize stockholder value, including strategic partnerships for its WTX-124 and WTX-330 INDUKINE programs, with no assurance any transaction will occur.
Werewolf Therapeutics, Inc. received an updated ownership report from investment entities Longwood Fund III, L.P. and Longwood Fund III GP, LLC. The Reporting Persons disclose beneficial ownership of 1,677,082 shares of Werewolf Therapeutics common stock, representing 3.5% of the class, as of the reported date.
The filing states that all reported shares are held of record by Longwood Fund III, with Longwood Fund III GP as its general partner sharing voting and dispositive power. The Reporting Persons indicate they own 5 percent or less of the outstanding common stock and certify the holdings are not for the purpose of changing or influencing control of the company.
Werewolf Therapeutics, Inc. received a Nasdaq notice on February 4, 2026, stating its common stock has closed below $1.00 per share for 30 consecutive business days, failing the Nasdaq Global Select Market minimum bid price requirement.
The company has an initial 180‑day grace period, until August 3, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days. If it does not regain compliance, it may seek an additional 180‑day period by transferring to the Nasdaq Capital Market, or its stock could ultimately face delisting, subject to appeal rights.
Werewolf Therapeutics director–affiliated funds reported a small share sale. On January 16, 2026, investment entities associated with director Luke Evnin sold a total of 38,782 shares of Werewolf Therapeutics, Inc. common stock under a pre‑established Rule 10b5-1 trading plan dated September 24, 2025.
The weighted average sale price was $0.54 per share, with individual trades executed between $0.535 and $0.5495. The shares were sold by several MPM-managed entities, including AM LLC, MPM BioVentures 2014 funds, AM BV2014 and MPM Oncology Innovations Fund. After these transactions, entities associated with Evnin indirectly held 2,159,860 shares of Werewolf Therapeutics across these vehicles, and he disclaims beneficial ownership beyond his pecuniary interest.
Werewolf Therapeutics, Inc. received an Amendment No. 5 to a Schedule 13D from a group of investment funds and individuals associated with MPM and UBS Oncology updating their ownership in the company’s common stock. The filing lists multiple reporting persons, including MPM BioVentures 2014, L.P., UBS Oncology Impact Fund L.P., MPM BioImpact LLC and individuals Ansbert Gadicke, Luke Evnin and Todd Foley.
Ansbert Gadicke is reported as beneficially owning 3,368,670 shares, or 6.9% of the common stock, while Luke Evnin and Todd Foley are reported at 4.4% and 3.3%, respectively. The filing states that these percentages are based on 48,540,200 shares of common stock outstanding as of October 29, 2025. Various MPM-managed funds hold additional stakes through complex general partner and managing member relationships.
The reporting persons also disclose a series of open‑market sales of Werewolf common stock since the prior amendment, from December 30, 2025 through January 16, 2026. On each trading day in this period, affiliated funds such as BV 2014, BV 2014(B), AM BV2014 LLC, MPM Oncology Innovations Fund, MPM Asset Management LLC and UBS Oncology sold blocks of shares at average prices generally between about $0.54 and $0.65 per share.
Werewolf Therapeutics director Luke Evnin, through affiliated investment entities, reported indirect sales of common stock of Werewolf Therapeutics, Inc. over three trading days in January 2026. The transactions were executed under a pre-established Rule 10b5-1 trading plan dated September 24, 2025.
On January 13, 2026, affiliated entities sold 43,198 shares at a weighted average price of $0.55, leaving 2,266,671 shares indirectly beneficially owned. On January 14, 2026, they sold 30,616 shares at a weighted average price of $0.57, leaving 2,236,055 shares indirectly beneficially owned. On January 15, 2026, they sold 37,413 shares at a weighted average price of $0.55, leaving 2,198,642 shares indirectly beneficially owned.
The shares were held and sold by entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P. Evnin is associated with these entities and disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.